A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy

European Journal of Surgical Oncology

Volumn 32, Issue 6, 2006, Pages 655-660

  Yu, W ^a  

^a Kyungpook National University   (South Korea)

Author keywords

5 Fluorouracil; Adjuvant chemotherapy; Intraperitoneal chemotherapy; Mitomycin C; Stomach neoplasm

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; PICIBANIL; SCHIZOPHYLLAN; TEGAFUR; URACIL;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CASE MANAGEMENT; CHEMOSURGERY; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG INDICATION; GASTRECTOMY; HUMAN; LYMPHADENECTOMY; MICROMETASTASIS; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; INFUSIONS, PARENTERAL; MALE; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33746022008     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.03.010     Document Type: Article

References (45)

1. Sobin L.H., and Wittekind C. TNM classification of malignant tumors. 6th ed. (2002), Wiley-Liss, New York
2. Hermanek P., Henson D.E., Hutter R.V.P., and Sobin L.H. TNM supplement 1993. A commentary on uniform use (1993), Springer, Berlin
3. Roukos D.H. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 26 (2000) 243-255
4. Hermans J., Bonenkamp J.J., Boon M.C., Bunt A.M., Ohyama S., Sasako M., et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11 (1993) 1441-1447
5. Earle C.C., and Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 35 (1999) 1059-1064
6. Panzini I., Gianni L., Fattori P.P., Tassinari D., Imola M., Fabbri P., et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88 (2002) 21-27
7. Grau J.J., Martin M., Fuster J., Pera M., Garcia-Valdecasas J.C., Bombi J.A., et al. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer. J Surg Oncol 82 (2003) 234-240
8. Nakajima T., Nashimoto A., Kitamura M., Kito T., Iwanaga T., Okabayashi K., et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 354 (1999) 273-277
9. Neri B., de Leonardis V., Romano S., Andreoli F., Pernice L.M., Bruno L., et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 73 (1996) 549-552
10. Krook J.E., Wieand H.S., Beart R.W., Leigh J.E., Kugler J.W., Foley J.F., et al. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 67 (1991) 2454-2458
11. Coombes R.C., Schein P.S., Chilvers C.E., Wils J., Beretta G., Bliss J.M., et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. Clin Oncol 8 (1990) 1362-1369
12. Macdonald J.S., Fleming T.R., Peterson R.F., Berenberg J.L., McClure S., Chapman R.A., et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 2 (1995) 488-494
13. Tsavaris N., Tentas K., Kosmidis P., Mylonakis N., Sakelaropoulos N., Kosmas C., et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 42 (1996) 220-226
14. Engstrom P.F., Lavin P.T., Douglass H.O., and Brunner K.W. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 55 (1985) 1868-1873
15. Nakazato H., Koike A., Saji S., Ogawa N., and Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343 (1994) 1122-1126
16. Kim J.P., Kwon O.J., Oh S.T., and Yang H.K. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 216 (1992) 269-279
17. Maehara Y., Okuyama T., Kakeji Y., Baba H., Furusawa M., and Sugimachi K. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 168 (1994) 36-40
18. Fujimoto S., Furue H., Kimura T., Kondo T., Orita K., Taguchi T., et al. Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study. Eur J Cancer 27 (1991) 1114-1118
19. Ochiai T., Sato H., Sato H., Hayashi R., Asano T., Isono K., et al. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res 43 (1983) 3001-3007
20. Hallissey M.T., Dunn J.A., Ward L.C., and Allum W.H. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 343 (1994) 1309-1312
21. Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
22. Yoo C.H., Noh S.H., Shin D.W., Choi S.H., and Min J.S. Recurrence following curative resection for gastric carcinoma. Br J Surg 87 (2000) 236-242
23. Adachi Y., Oshiro T., Mori M., Maehara Y., and Sugimachi K. Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer 77 (1996) 2445-2448
24. Roviello F., Marrelli D., de Manzoni G., Morgagni P., Di Leo A., Saragoni L., et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 90 (2003) 1113-1119
25. Wu C.W., Lo S.S., Shen K.H., Hsieh M.C., Chen J.H., Chiang J.H., et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 27 (2003) 153-158
26. Athlin L., Lundskog B., Stenling R., and Eriksson S. Local recurrence and long-term survival in patients with gastric cancer-analysis of possible impact of clinicopathological parameters. Eur J Surg Oncol 21 (1995) 162-167
27. Landry J., Tepper J.E., Wood W.C., Moulton E.O., Koerner F., and Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 19 (1990) 1357-1362
28. Maehara Y., Hasuda S., Koga T., Tokunaga E., Kakeji Y., and Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87 (2000) 353-357
29. Maruyama K., Okabayashi K., and Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 11 (1987) 418-425
30. Averbach A.M., and Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 83 (1996) 726-733
31. Hagiwara A., Takahashi T., Kojima O., Sawai K., Yamaguchi T., Yamane T., et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339 (1992) 629-631
32. Rosen H.R., Jatzko G., Repse S., Potrc S., Neudorfer H., Sandbichler P., et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 16 (1998) 2733-2738
33. Atiq O.T., Kelsen D.P., Shiu M.H., Saltz L., Tong W., Niedzwiecki D., et al. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 11 (1993) 425-433
34. Sautner T., Hofbauer F., Depisch D., Schiessel R., and Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12 (1994) 970-974
35. Yu W., Whang I., Suh I., Averbach A., Chang D., and Sugarbaker P.H. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228 (1998) 347-354
36. Yonemura Y., Ninomiya I., Kaji M., Sugiyama K., Fujimura K., Sawa T., et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg 19 (1995) 450-455
37. Fujimoto S., Takahashi M., Mutou T., Kobayashi K., and Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 85 (1999) 529-534
38. Hamazoe R., Maeta M., and Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73 (1994) 2048-2052
39. Kunisaki C., Shimada H., Nomura M., Akiyama H., Takahashi M., and Matsuda G. Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. Surgery 131 (2002) 521-528
40. Yu W., Whang I., Chung H.Y., Averbach A., and Sugarbaker P.H. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25 (2001) 985-990
41. Marrelli D., Roviello F., de Manzoni G., Morgagni P., Di Leo A., Saragoni L., et al. Different patterns of recurrence in gastric cancer depending on Lauren's histological type: longitudinal study. World J Surg 26 (2002) 1160-1165
42. Lee C.C., Lo S.S., Wu C.W., Shen K.H., Li A.F., Hsieh M.C., et al. Peritoneal recurrence of gastric adenocarcinoma after curative resection. Hepatogastroenterology 50 (2003) 1720-1722
43. Nakajima T., Harashima S., Hirata M., and Kajitani T. Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytol 22 (1978) 225-229
44. Abe S., Yoshimura H., Tabara H., Tachibana M., Monden N., Nakamura T., et al. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome. J Surg Oncol 59 (1995) 226-229
45. Chung H.Y., and Yu W. The patterns of recurrence after curative resection in gastric cancer. J Kor Surg Soc 59 (2000) 765-770